Literature DB >> 6719258

The conservative treatment of sciatica.

G R Bell, R H Rothman.   

Abstract

The mainstay of rational treatment of acute sciatica involves bed rest and antiinflammatory drugs. The authors recommended 2 weeks of complete bed rest with progressive gradual mobilization over the next 7-10 days. Buffered aspirin in a dosage of 10-15 grains every 4 hours is prescribed both for its analgesic effect as well as for its antiinflammatory properties. Through the low-back school, the patient is instructed in low-back hygiene. Physically capable patients are encouraged to begin an aerobic exercise program. In the absence of absolute indications for surgery (cauda equina syndrome or marked progressive muscle weakness) it seems reasonable to permit up to 3 months of conservative therapy before recommending surgery.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6719258     DOI: 10.1097/00007632-198401000-00012

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  5 in total

1.  What types of degenerative lumbar pathologies respond to nerve root injection? A retrospective review of six hundred and forty one cases.

Authors:  Masahiro Kanayama; Fumihiro Oha; Tomoyuki Hashimoto
Journal:  Int Orthop       Date:  2015-04-16       Impact factor: 3.075

Review 2.  Recent advances in the treatment of low back pain.

Authors:  A Nachemson
Journal:  Int Orthop       Date:  1985       Impact factor: 3.075

3.  Outpatient treatment of lumbar disc sciatica.

Authors:  R L Swezey; J O Crittenden; A M Swezey
Journal:  West J Med       Date:  1986-07

4.  Low back pain exacerbated by psychosocial factors.

Authors:  V J Derebery; W H Tullis
Journal:  West J Med       Date:  1986-05

5.  The effectiveness of motorised lumbar traction in the management of LBP with lumbo sacral nerve root involvement: a feasibility study.

Authors:  Annette A Harte; George D Baxter; Jacqueline H Gracey
Journal:  BMC Musculoskelet Disord       Date:  2007-11-29       Impact factor: 2.362

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.